EBITDA (Annual)

EBITDA: Income before interest, taxes, depreciation and amortization.

Karyopharm Therapeutics Inc. (KPTI) had EBITDA of $-80.28M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$146.07M
Net Income	$-196.04M
Cost of Goods Sold	$5.95M
Gross Profit	$140.12M
Operating Expenses	$236.77M
Operating Income	$-90.71M
Non-Operating Income/Expense	$-105.29M
Pre-Tax Income	$-196.00M
Normalized Pre-Tax Income	$-196.00M
Income after Taxes	$-196.04M
Income from Continuous Operations	$-196.04M
Consolidated Net Income/Loss	$-196.04M
Normalized Income after Taxes	$-196.04M
EBIT	$-90.71M
EBITDA	$-80.28M
Weighted-Average Shares Outstanding (Basic)	10.94M
Weighted-Average Shares Outstanding (Diluted)	10.94M
Earnings per Share (EPS) (Basic)	$-17.93
Earnings per Share (EPS) (Diluted)	$-17.93
Balance Sheet Financials
Current Assets	$103.15M
Property, Plant, and Equipment	$0.10M
Long-Term Assets	$5.27M
Total Assets	$108.42M
Current Liabilities	$92.06M
Long-Term Debt	$205.88M
Long-Term Liabilities	$309.28M
Total Liabilities	$401.34M
Common Equity	$-292.93M
Tangible Shareholders Equity	$-292.93M
Shareholders Equity	$-292.93M
Common Shares Outstanding	18.31M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-75.37M
Cash Flow from Investing Activities	$43.38M
Cash Flow from Financial Activities	$30.05M
Beginning Cash	$62.81M
End Cash	$60.89M
Increase/Decrease in Cash	$-1.92M
Stock-Based Compensation	$14.05M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.12
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-2.37
Debt to Equity Ratio	-0.77
Gross Margin	95.93%
Operating Margin	-62.10%
EBIT Margin	-62.10%
EBITDA Margin	-54.96%
Pre-Tax Profit Margin	-134.18%
Profit Margin	-134.21%
Free Cash Flow	$-75.37M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	1.35
Inventory Turnover	1.47
Receiveable Turnover	5.58
Days Sales in Receivables	65.42
Return on Equity	66.92%
Return on Tangible Equity	66.92%
Return on Assets	-180.82%
Return on Investments	225.23%
Book Value Per Share	$-16.00
Free Cash Flow per Share	$-6.89
Operating Cash Flow per Share	$-6.89

Data from Zacks Investment Research, Inc.